Cargando…

Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study

PURPOSE: Hyponatremia secondary to SIADH is frequent in cancer patients and potentially deleterious. The aim of this sub-analysis of the Hyponatremia Registry database is to analyze current diagnostic and therapeutic management practices in cancer patients with SIADH. METHODS: We analyzed 358 cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Burst, Volker, Grundmann, Franziska, Kubacki, Torsten, Greenberg, Arthur, Rudolf, Despina, Salahudeen, Abdulla, Verbalis, Joseph, Grohé, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445151/
https://www.ncbi.nlm.nih.gov/pubmed/28255808
http://dx.doi.org/10.1007/s00520-017-3638-3
_version_ 1783238824105607168
author Burst, Volker
Grundmann, Franziska
Kubacki, Torsten
Greenberg, Arthur
Rudolf, Despina
Salahudeen, Abdulla
Verbalis, Joseph
Grohé, Christian
author_facet Burst, Volker
Grundmann, Franziska
Kubacki, Torsten
Greenberg, Arthur
Rudolf, Despina
Salahudeen, Abdulla
Verbalis, Joseph
Grohé, Christian
author_sort Burst, Volker
collection PubMed
description PURPOSE: Hyponatremia secondary to SIADH is frequent in cancer patients and potentially deleterious. The aim of this sub-analysis of the Hyponatremia Registry database is to analyze current diagnostic and therapeutic management practices in cancer patients with SIADH. METHODS: We analyzed 358 cancer patients who had serum sodium concentration ([Na(+)]) ≤ 130 mEq/L and a clinical diagnosis of SIADH from 225 sites in the USA and EU. RESULTS: Precise diagnostic testing was performed in only 46%. Almost 12% of all patients did not receive any hyponatremia treatment. The most frequent therapies were fluid restriction (20%), isotonic saline (14%), fluid restriction/isotonic saline (7%), tolvaptan (8%), and salt tablets (7%). Hypertonic saline was used in less than 3%. Tolvaptan produced the greatest median rate of [Na(+)] change (IQR) (3.0 (4.7) mEq/L/day), followed by hypertonic saline (2.0(7.0) mEq/L/day), and fluid restriction/isotonic saline (1.9(3.2) mEq/L/day). Both fluid restriction and isotonic saline monotherapies were significantly less effective (0.8(2.0) mEq/L/day and 1.3(3.0) mEq/L/day, respectively) and were associated with clinically relevant rates of treatment failure. Only 46% of patients were discharged with [Na(+)] ≥ 130 mEq/L. Overly rapid correction of hyponatremia occurred in 11.7%. CONCLUSIONS: Although essential for successful hyponatremia management, appropriate diagnostic testing is not routinely performed in current practice. The most frequently employed monotherapies were often ineffective and sometimes even aggravated hyponatremia. Tolvaptan was used less often but showed significantly greater effectiveness. Despite clear evidence that hyponatremia is associated with poor outcome in oncology patients, most patients were discharged still hyponatremic. Further studies are needed to assess the beneficial impact of hyponatremia correction with effective therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-017-3638-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5445151
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-54451512017-06-06 Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study Burst, Volker Grundmann, Franziska Kubacki, Torsten Greenberg, Arthur Rudolf, Despina Salahudeen, Abdulla Verbalis, Joseph Grohé, Christian Support Care Cancer Original Article PURPOSE: Hyponatremia secondary to SIADH is frequent in cancer patients and potentially deleterious. The aim of this sub-analysis of the Hyponatremia Registry database is to analyze current diagnostic and therapeutic management practices in cancer patients with SIADH. METHODS: We analyzed 358 cancer patients who had serum sodium concentration ([Na(+)]) ≤ 130 mEq/L and a clinical diagnosis of SIADH from 225 sites in the USA and EU. RESULTS: Precise diagnostic testing was performed in only 46%. Almost 12% of all patients did not receive any hyponatremia treatment. The most frequent therapies were fluid restriction (20%), isotonic saline (14%), fluid restriction/isotonic saline (7%), tolvaptan (8%), and salt tablets (7%). Hypertonic saline was used in less than 3%. Tolvaptan produced the greatest median rate of [Na(+)] change (IQR) (3.0 (4.7) mEq/L/day), followed by hypertonic saline (2.0(7.0) mEq/L/day), and fluid restriction/isotonic saline (1.9(3.2) mEq/L/day). Both fluid restriction and isotonic saline monotherapies were significantly less effective (0.8(2.0) mEq/L/day and 1.3(3.0) mEq/L/day, respectively) and were associated with clinically relevant rates of treatment failure. Only 46% of patients were discharged with [Na(+)] ≥ 130 mEq/L. Overly rapid correction of hyponatremia occurred in 11.7%. CONCLUSIONS: Although essential for successful hyponatremia management, appropriate diagnostic testing is not routinely performed in current practice. The most frequently employed monotherapies were often ineffective and sometimes even aggravated hyponatremia. Tolvaptan was used less often but showed significantly greater effectiveness. Despite clear evidence that hyponatremia is associated with poor outcome in oncology patients, most patients were discharged still hyponatremic. Further studies are needed to assess the beneficial impact of hyponatremia correction with effective therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-017-3638-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-03-02 2017 /pmc/articles/PMC5445151/ /pubmed/28255808 http://dx.doi.org/10.1007/s00520-017-3638-3 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Burst, Volker
Grundmann, Franziska
Kubacki, Torsten
Greenberg, Arthur
Rudolf, Despina
Salahudeen, Abdulla
Verbalis, Joseph
Grohé, Christian
Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study
title Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study
title_full Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study
title_fullStr Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study
title_full_unstemmed Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study
title_short Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study
title_sort euvolemic hyponatremia in cancer patients. report of the hyponatremia registry: an observational multicenter international study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445151/
https://www.ncbi.nlm.nih.gov/pubmed/28255808
http://dx.doi.org/10.1007/s00520-017-3638-3
work_keys_str_mv AT burstvolker euvolemichyponatremiaincancerpatientsreportofthehyponatremiaregistryanobservationalmulticenterinternationalstudy
AT grundmannfranziska euvolemichyponatremiaincancerpatientsreportofthehyponatremiaregistryanobservationalmulticenterinternationalstudy
AT kubackitorsten euvolemichyponatremiaincancerpatientsreportofthehyponatremiaregistryanobservationalmulticenterinternationalstudy
AT greenbergarthur euvolemichyponatremiaincancerpatientsreportofthehyponatremiaregistryanobservationalmulticenterinternationalstudy
AT rudolfdespina euvolemichyponatremiaincancerpatientsreportofthehyponatremiaregistryanobservationalmulticenterinternationalstudy
AT salahudeenabdulla euvolemichyponatremiaincancerpatientsreportofthehyponatremiaregistryanobservationalmulticenterinternationalstudy
AT verbalisjoseph euvolemichyponatremiaincancerpatientsreportofthehyponatremiaregistryanobservationalmulticenterinternationalstudy
AT grohechristian euvolemichyponatremiaincancerpatientsreportofthehyponatremiaregistryanobservationalmulticenterinternationalstudy